154 related articles for article (PubMed ID: 30540119)
1. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.
Campolina AG
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e470s. PubMed ID: 30540119
[TBL] [Abstract][Full Text] [Related]
2. Approaches to Capturing Value in Oncology.
Walter E
Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
[TBL] [Abstract][Full Text] [Related]
3. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
4. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
[TBL] [Abstract][Full Text] [Related]
5. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
Neumann PJ; Willke RJ; Garrison LP
Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
[TBL] [Abstract][Full Text] [Related]
6. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
[TBL] [Abstract][Full Text] [Related]
7. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
[TBL] [Abstract][Full Text] [Related]
8. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks.
Cohen JT; Anderson JE; Neumann PJ
Value Health; 2017 Feb; 20(2):193-199. PubMed ID: 28237194
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
11. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
Waldeck AR; Botteman MF; White RE; van Hout BA
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
[TBL] [Abstract][Full Text] [Related]
12. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.
Slomiany M; Madhavan P; Kuehn M; Richardson S
Am Health Drug Benefits; 2017 Jul; 10(5):253-260. PubMed ID: 28975009
[TBL] [Abstract][Full Text] [Related]
13. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
Mandelblatt JS; Ramsey SD; Lieu TA; Phelps CE
Value Health; 2017 Feb; 20(2):185-192. PubMed ID: 28237193
[TBL] [Abstract][Full Text] [Related]
15. Value assessment of oncology drugs using a weighted criterion-based approach.
Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
[TBL] [Abstract][Full Text] [Related]
16. Multicriteria decision analysis in oncology.
Adunlin G; Diaby V; Montero AJ; Xiao H
Health Expect; 2015 Dec; 18(6):1812-26. PubMed ID: 24635949
[TBL] [Abstract][Full Text] [Related]
17. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
Westrich K; Buelt L; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
[TBL] [Abstract][Full Text] [Related]
18. Verifying the value of existing frameworks for formulary review at a large academic health system: assessing inter-rater reliability.
Karas BL; Picone MF; Werner S; Holsopple M
J Manag Care Spec Pharm; 2021 Apr; 27(4):488-496. PubMed ID: 33769852
[No Abstract] [Full Text] [Related]
19. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
20. Value of information analysis in oncology: the value of evidence and evidence of value.
Tuffaha HW; Gordon LG; Scuffham PA
J Oncol Pract; 2014 Mar; 10(2):e55-62. PubMed ID: 24194511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
